A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 21 Sep 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 02 Aug 2012 Planned end date changed from 1 Feb 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
- 27 Sep 2011 Planned end date changed from 1 Jul 2010 to 1 Feb 2012 as reported by ClinicalTrials.gov.